Drugs / VIAject™
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01000922 | Jun 2006 → Jan 2008 | diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT00875108 | Jul 2007 → Jan 2010 | type 2 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 3 | NCT00875459 | Apr 2007 → Feb 2010 | type 1 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 3 | NCT00542633 | Dec 2006 → Aug 2008 | type 2 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 3 | NCT00542724 | Sep 2006 → Jul 2008 | type 1 diabetes mellitus | Biodel | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIAject | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01000922 ↗ |
| Modality | Protein / enzyme biologic | “when used as prandial insulin” NCT00875108 ↗ |
| Route | Subcutaneous | “Subcutaneous injection 25 IU/mL” NCT00875108 ↗ |